venous%20thromboembolism%20-%20management
VENOUS THROMBOEMBOLISM - MANAGEMENT
Deep vein thrombosis is a frequent manifestation of venous thromboembolism in which there is a blood clot blocking a deep vein.
Clinical findings are important to the diagnosis of deep vein thrombosis but are poor predictors of the presence or severity of thrombosis.
Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially veins in the legs and pelvis.
Dyspnea, pleuritic chest pain, syncope and tachypnea occur in most cases of pulmonary embolism.
Massive pulmonary embolism has the prime symptom of dyspnea and systemic arterial hypotension that requires pressor support is the predominant sign.

Patient Education

  • Educate patients and their families about DVT/PE, especially risk of recurrence of disease, risk of long-term disability and about the possibility of genetic predisposition
  • Explain treatment options to patients and discuss the benefits, risks and side effects of anticoagulation therapy
  • Discuss lifestyle issues with patients
  • Advise patients to drink plenty of fluids
  • Lay public may not be familiar with PE and discussing it may assuage their emotional burden
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Tristan Manalac, 26 Sep 2017
Depression seems to be a significant independent predictor of recurrent chest pain (RCP) in patients with acute chest pain, regardless of cardiac ischaemia, a recent study has shown.
Pank Jit Sin, 22 Sep 2015
When it comes to information and health advice about erectile dysfunction (ED), Malaysian men may be barking up the wrong tree, reveals a survey. 
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
10 Jan 2018

A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.